Search Results for: 19

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3 October 03, 2024 08:00 ET ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat […]

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

September 26, 2024 21:06 ET ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the

Theriva Biologics Announces Pricing of $2.5 Million Public Offering Read More »

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

September 23, 2024 08:00 ET – Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months – ROCKVILLE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Read More »

Theriva™ Biologics logra el objetivo de inscripción de pacientes en VIRAGE, el ensayo de Fase 2b de VCN-01 con gemcitabina/nab-paclitaxel para el tratamiento del cáncer de páncreas metastásico

September 23, 2024 08:00 ET – Objetivo de 92 pacientes evaluables (46 en la rama de control y 46 en la rama de tratamiento con VCN-01) inscritos en 15 centros de España y EE. UU. en un plazo de 21 meses – ROCKVILLE, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX),

Theriva™ Biologics logra el objetivo de inscripción de pacientes en VIRAGE, el ensayo de Fase 2b de VCN-01 con gemcitabina/nab-paclitaxel para el tratamiento del cáncer de páncreas metastásico Read More »

Theriva™ Biologics obtiene financiación para la fabricación del plan nacional de transferencia de conocimiento del Gobierno español

Theriva Biologics y la Universidad Autónoma de Barcelona recibirán un total de 2,28 millones de euros en apoyo del proyecto THERICEL, una plataforma de células en suspensión para la producción de terapias basadas en virus September 16, 2024 08:00 ET ROCKVILLE, Maryland, Sept. 16, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX) («Theriva» o

Theriva™ Biologics obtiene financiación para la fabricación del plan nacional de transferencia de conocimiento del Gobierno español Read More »

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies September 16, 2024 08:00 ET ROCKVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program Read More »

Theriva Biologics anuncia el desdoblamiento inverso de sus acciones

August 17, 2024 12:58 ET ROCKVILLE, Md., Aug. 17, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar enfermedades en áreas de gran carencia, ha anunciado hoy un desdoblamiento inverso de sus acciones ordinarias emitidas y en circulación, con un valor nominal

Theriva Biologics anuncia el desdoblamiento inverso de sus acciones Read More »

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

August 13, 2024 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- – Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2024

August 13, 2024 15:09 ET – Se espera que la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico (PDAC), finalice en el tercer trimestre de 2024 – – Obtención de la designación de vía rápida (FTD) concedida por la Administración de Alimentos

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2024 Read More »